Heart disease remains the leading cause of death in the United States, with nearly a million fatal cases reported every year, equating to approximately one heart disease related death every 34 seconds. However, modern medicine is no longer limited to treating what goes wrong. Scientists are now focused on making some of those deaths preventable by developing treatments that address the genetic root of the problem.
For many cardiac conditions, the underlying issue is a genetic mutation that disrupts how heart muscle cells contract, transmit electrical signals, and repair injury. Although medication can help lessen these effects and corrective surgery can repair some of the resulting damage, neither approach addresses the underlying genetic defect. Gene therapies are designed to do exactly that.
What Is Cardiac Gene Therapy?
Heart disease is complex, and there is no single isolated cause, rather than managing or repairing the symptoms of a cellular mutation, cardiac gene therapy aims to correct the underlying genetic code responsible for the disruption.
By delivering corrective genetic material directly into cardiac cells, gene therapy could help restore normal cellular function and provide benefits beyond what heart disease treatment can achieve.
How Gene Therapy Vectors Work
Gene therapy for heart disease introduces therapeutic genetic material into cardiovascular cells using a carrier and a physical path into heart tissue. The carrier (vector) protects the genetic payload from breaking down while ensuring it enters the correct cells. Vectors also drive therapeutic gene expression once the payload arrives.
The most widely used vectors are adeno-associated viruses (AAVs), which target cardiovascular musculature at the cellular level. AAVs are engineered without the ability to replicate or cause infection, instead transforming into protein shells that transport therapeutic genes to the targeted cells.
Once injected, AAV shells bind to receptors, get pulled inside the cell, travel to the nucleus, and release the therapeutic genetic material. Cardiovascular cells read the new genetic instructions and begin producing tailored proteins, depending on the treatment.
Several AAV serotypes prefer cardiac muscle cells, while others target the liver, the eye, or the central nervous system. Tissue specificity is often why scientists choose AAVs as the dominant platform across gene therapy for heart disease, with more than 300 clinical trials and six FDA-approved therapies on record as of 2025.
AAV Gene Therapy Limitations and Vector Alternatives
Adeno-associated viruses in gene therapy may not be suitable for every patient. Specifically, many patients carry pre-existing antibodies against AAV serotypes, which can neutralize the vector before it reaches the heart tissue.
AAV vectors also have a packaging limit, which can’t exceed 4.7 kilobases of DNA. That restriction excludes delivery of many larger therapeutic genes. In response, researchers have developed two parallel vector alternatives:
- Lipid Nanoparticles — Can carry genetic payloads without triggering pre-existing immune responses.
- Engineered Synthetic Capsids — Can evade immune recognition and extend gene expression durability.
Alternative gene therapy vectors, such as lipid nanoparticles and engineering synthetic capsids each have advantages and limitations that must be considered.. For instance, lipid nanoparticles can accumulate in the liver, further limiting how much reaches critical cardiac tissue. Additionally,engineered synthetic capsids have yet to be tested on a clinical scale.
Comparing Gene Therapy Delivery Methods
Coronary Infusion via Catheter
Coronary infusion is the only gene therapy delivery method to undergo large-scale clinical trials. In this approach, clinicians guide a catheter to the coronary arteries, infusing the vector directly into circulation, where it crosses the vessel wall and enters the cardiac muscle.
A key limitation is that the procedure’s efficiency can decrease with continuous infusion because of vector wash-out before crossing into cardiomyocytes. Researchers have begun creating flow-control methodologies to address vector wash-out, including coronary artery balloon occlusion, which helps trap the vector in circulation during injection.
Direct Intramyocardial Injection
Utilizing catheter-based electromechanical mapping, medical professionals generate an image of cardiovascular electromagnetic activity to bypass the vascular barrier and position the vector directly inside the cardiac muscle. This direct intramyocardial injection can produce the highest local gene expression of all gene therapy delivery methods.
The primary limitation of direct intramyocardial injection for gene therapy is distribution. Injections create concentrated deposits near the entry point rather than uniformly distributing across vascular walls. Often, this means a significant clinical advantage for focal applications targeting scar border zones driving post-infarction arrhythmia.
Epicardial Gene Painting
Epicardial gene painting (EGP) applies the vector to the epicardium during an open-chest surgical procedure. Medical professionals distribute the vector solution across exposed cardiac tissue to target abnormalities without introducing vectors into circulation.
The EGP vector delivery method has practical limitations, including requiring surgical intervention and uniform vector solution distribution across an irregular beating surface. Moreover, EGP gene expression is largely confined to epicardial cells rather than penetrating deeper into myocardial layers.
Systemic Bloodstream Injection
Systemic bloodstream injection allows the gene therapy vector to circulate throughout the body through intravenous inoculation. As the least invasive delivery method for cardiovascular gene therapy, continual studies remain underway to determine effectiveness, safety, and long-term viability in human subjects.
In bloodstream injections of gene therapy vectors, the liver often intercepts a vast portion of the circulating vector. However, increasing dosage is not the answer. Achieving therapeutic cardiac gene expression via systemic bloodstream injection would require AAV doses associated with hepatotoxicity.
| Coronary Infusion via Catheter | Direct Intramyocardial Injection | Epicardial Gene Painting | Systemic Bloodstream Injection | |
| Invasiveness | Moderate | High | High | Minimal |
| Myocardial Distribution | Broad | Focal-concentrated | Surface only | Whole body |
| Transduction Efficiency | Moderate | Locally high | Moderate | Low cardiac |
Considerations in Cardiac Gene Therapy Delivery
The optimal approach to cardiac gene therapy delivery depends on the condition, the heart disease distribution within vascular cells, and the patient’s procedural tolerance. Additional challenges can also arise when targeting specific cardiac cells.
Moreover, viral and non-viral vectors provide unique benefits and limitations that can impact how each delivery method performs.
Transduction Efficiency
- Delivery routes move therapeutic genes into cells at different rates
- Sufficient cardiac uptake has not been achieved across all delivery methods
- Increased vector dosages can offset poor cardiac targeting
- Vector dosage determines the gene therapy delivery method
Distribution Pattern
- Heart failure spanning the ventricular wall demands whole-muscle coverage
- Arrhythmia therapies for discrete scar border zones require targeted delivery
- Misdirected expression of therapeutic genes can cause adverse effects
Off-Target Expression
- AAV-associated liver injury and lipid nanoparticle-associated immune activation
- Vector and delivery pairings produce unique distribution and toxicity profiles
- Bloodstream delivery exposes other organs to vector concentrations
How a vector reaches cardiac tissue is often the limiting factor between a pre-clinically effective gene therapy and one that produces meaningful outcomes for patients. Each route presents a distinct profile, and no single method has been proven advantageous across all cardiac indicators.
FAQs
Active clinical programs now target inherited arrhythmias, cardiomyopathies, and heart failure. The following questions are to help support conversations between potential gene therapy patients and their cardiovascular care team.
Q: Is my heart condition caused by a genetic mutation?
A: Genetic testing is a crucial diagnostic tool in cardiovascular medicine. Doctors use it to identify pathogenic variants to determine whether a tailored gene therapy program exists or is appropriate for the patient’s care plan.
Q: Am I eligible for any clinical trials on gene therapy?
A: Gene therapy clinical trial eligibility is determined by disease severity, condition type, treatment history, age, and serological factors, including pre-existing AAV antibody titers.
Q: What immune screening is required before treatment?
A: Pre-existing AAV antibodies can disqualify patients from some clinical trials or reduce gene therapy efficacy. Many programs involve serological screenings as part of the initial assessment.
Current Standing and Clinical Outlook
Within a single research generation, the development of cardiac gene therapy has gone from a theoretical approach to a published clinical discipline. While meaningful challenges remain, each represents a potential for investigation and innovation.
Visit the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) to follow the latest developments in cardiovascular gene therapy research.
